This trial is evaluating whether Cediranib will improve 1 primary outcome, 6 secondary outcomes, and 2 other outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to 2 weeks prior to start of therapy.
This trial requires 90 total participants across 2 different treatment groups
This trial involves 2 different treatments. Cediranib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Prostate cancer is a form of cancer that forms in the prostate gland. Men with prostate cancer are typically diagnosed after they are diagnosed with a low grade form of prostate cancer. Some men with high stage prostate cancer develop bone metastasis. When it affects males in the US the average life span following prostate cancer is 4-5 years.\nprostate cancer question: Does acupuncture increase prostate specific antigen levels in men with and without prostate cancer? answer: Acupuncture alone does not affect serum PSA levels in healthy men and the short-term clinical effectiveness of acupuncture should not be used as a marker or surrogate for prostate cancer.
The initial treatment of localized [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) includes simple observation or watchful waiting. Lifestyle changes such as exercise may positively influence outcomes from prostate cancer as well as reduce cancer-related morbidity and mortality. Lifestyle modification and exercise may also help prevent prostate cancer.
These data, obtained from the use of a number of prospective control groups with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) disease, suggest that the likelihood of the patient's disease remaining in the body after treatment is greater than in any other cancer. This has ramifications on patients' fears regarding cancer cure, and the likelihood of people accepting cancer treatment regimes that would result in the deaths of patients without cure.
As prostate cancer is diagnosed at relatively late stages, prevention methods should include health care education about the prevention, early diagnosis, and treatment of prostate cancer. A low-fat, low-calorie, and low-sugar diet seems reasonable.
As we see in every tumor center and referral center the signs are variable. In our opinion there are two essential clues, a prostatic mass, and palpable prostatic veins. A prostatic mass may have other features. A palpable prostatic vein indicates metastatic disease from other locations. Tumor-derived PSA can be seen in up to 20% of cases.
Approximately 474,200 men will be diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) a year in the United States. Over 70% of those diagnosed will be screened by biopsy or autopsy. Prostate cancer remains a major health concern for men, and has accounted for 30% of all cancer deaths in the United States each year.
Although the exact treatment plans for patients with prostate cancer are largely determined by factors such as the patient's specific and individual characteristics, advances in diagnostics and therapy have significantly benefited patients with prostate cancer, and improved outcomes and quality of life. The treatment options for prostate cancer depend on the extent and type of the initial disease, progression to metastatic disease from castrate-responsive disease, and overall patient prognosis.
Men should be asked about previous exposure to other cancers and their treatment details including hormone replacement therapy (HRT). A risk is present for prostate cancer for patients who have never used HRT. This may be especially so if the patient has a family history of prostate cancer or a family history of colorectal cancer has occurred. Other risk factors include smoking, excess body weight, alcoholism, low physical activity, and diabetes. A previous negative screening result, a positive screening result or, for men previously diagnosed with prostate cancer, a risk factor. However, many physicians are unfamiliar with the concept of prostate cancer risk, so it is important for patients and their physicians.
New drug development results for cediranib were promising. Cediranib may decrease PSA levels, with fewer side effects compared with sunitinib or sorafenib. Censure analyses from Novartis must acknowledge that the development of these agents is still under way at the time the report was written. Future trials may need to include a direct comparison of cediranib with current therapeutics before any firm conclusions regarding cediranib can be drawn.
Men diagnosed with prostate cancer at age 60 years and over are more likely to have a family history of the disorder. A higher mortality rate is noted at this age of the patient, which is attributed to death from prostate cancer in the later stages of life.
Cediranib is well tolerated in [metastatic [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)](https://www.withpower.com/clinical-trials/metastatic-prostate-cancer) patients who received prior chemotherapy, and provides a meaningful survival benefit compared with a placebo. Therefore, patients with metastatic prostate cancer should be offered cediranib in clinical trials. Because cediranib might be approved for locally advanced or metastatic cancers after prior chemoradiation, it may be useful for patients with localized prostate cancer as well as for those with unresectable local disease who are unsuitable for definitive radiotherapy.
Cediranib is the first FDA-approved dual PI3K/mTOR inhibitor. This potent inhibitor of proliferation and cell migration is an exciting novel oral agent that can reverse the growth stimulators that are typically co-opted by all mTOR kinases, including those expressed by the EGFR and IGF1-R, and is therefore a potential option for the treatment of a wide variety of different cancers.